As of 2025-01-13, the Relative Valuation of Revance Therapeutics Inc (RVNC) is (34.14) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.25 USD, the upside of Revance Therapeutics Inc based on Relative Valuation is -1150.6%.
The range of the Relative Valuation is (21.63) - (42.69) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.2x - 24.2x | 19.2x |
| Forward P/E multiples | 11.7x - 24.8x | 19.4x |
| Fair Price | (21.63) - (42.69) | (34.14) |
| Upside | -765.4% - -1413.4% | -1150.6% |
| Date | P/E |
| 2025-01-10 | -1.84 |
| 2025-01-08 | -1.92 |
| 2025-01-07 | -1.93 |
| 2025-01-06 | -1.96 |
| 2025-01-03 | -1.75 |
| 2025-01-02 | -1.73 |
| 2024-12-31 | -1.72 |
| 2024-12-30 | -1.73 |
| 2024-12-27 | -1.73 |
| 2024-12-26 | -1.74 |
| 2024-12-24 | -1.74 |
| 2024-12-23 | -1.74 |
| 2024-12-20 | -1.75 |
| 2024-12-19 | -1.74 |
| 2024-12-18 | -1.74 |
| 2024-12-17 | -1.74 |
| 2024-12-16 | -1.75 |
| 2024-12-13 | -1.74 |
| 2024-12-12 | -1.75 |
| 2024-12-11 | -1.72 |
| 2024-12-10 | -1.71 |
| 2024-12-09 | -1.71 |
| 2024-12-06 | -2.16 |
| 2024-12-05 | -2.23 |
| 2024-12-04 | -2.36 |
| 2024-12-03 | -2.22 |
| 2024-12-02 | -2.11 |
| 2024-11-29 | -2.04 |
| 2024-11-27 | -2.14 |
| 2024-11-26 | -2.28 |
| 2024-11-25 | -2.15 |
| 2024-11-22 | -2.11 |
| 2024-11-21 | -2.17 |
| 2024-11-20 | -2.15 |
| 2024-11-19 | -2.13 |
| 2024-11-18 | -2.26 |
| 2024-11-15 | -2.36 |
| 2024-11-14 | -2.44 |
| 2024-11-13 | -2.40 |
| 2024-11-12 | -2.34 |
| 2024-11-11 | -1.95 |
| 2024-11-08 | -2.09 |
| 2024-11-07 | -3.27 |
| 2024-11-06 | -3.29 |
| 2024-11-05 | -3.31 |
| 2024-11-04 | -3.29 |
| 2024-11-01 | -3.28 |
| 2024-10-31 | -3.34 |
| 2024-10-30 | -3.35 |
| 2024-10-29 | -3.34 |